不同药物和剂量静脉溶栓治疗急性心肌梗塞92例初步观察

A Primary observation of therapy with thrombolitic agents of different agents and doses for myocardiol infarction in cases

采用日本绿十字尿激酶(UK);美国,德国链激酶(SK)静滴治疗急性心肌梗塞92例.根据临床指标判定血管再通率分别为UK96万IU组50.0%(17/34),UK150万IU组61.9%(13/21),SK150万IU组64.8%(24/37).UK剂量加大,出血未增加,SK的轻度出血、过敏、低血压略高于Uk,但均不严重,容易处理.

Ninety two cases with acute myocardial infarction (AMI) were treated by intra-venous streptokinase (SK ) ,Urokinase (UK ) (Green Cross company ,Japan). The reper-fusion rates were 50. 0% (17/34), 61. 9% (13/21), 64. 8%(24/37) in group I (UK 960000U), group Ⅱ(UK 1. 5million U), group Ⅲ (SK 1. 5million U) respectively. Mild hemorrhag occured in 8. 8% (3/34) of group I, 4. 7%(1/21) of group Ⅱ, 16. 2% (6/37) of group Ⅲ respectively. There were no major bleeding or intracranial hem-orrhage. Hyportension was seen in 9. 1 % (5/55) of group I,Ⅱ and in 16. 2%(6/37) of group Ⅲ , skin rashes was found in one case of group Ⅲ , Total five week mortality was 7.8%(7/92). The study demonstrated that increasing UK dosege improved the reperfusion rates without Increasing the risk of bleeding. The efficacy of UK (l.5million U) and SK (1. 5million U ) is similar. Though mild hemorrhage, allergic reaction and hypotension were more com-mon in SK group than in UK groups. Which were not severe and treatment were easier, UK (1. 5million U ) and SK (1. 5mil-lion U ) were both effective and safe throm-bolytic therapy for AMI.